Trulieve heads into its third-quarter report with an unusual split between the stock and the spreadsheets. Shares have climbed more than 22% since the last report, while the broader market has gone nowhere. Yet the consensus model calls for revenue well below what the company just delivered. That gap between an enthusiastic tape and a conservative revenue forecast is the central tension going into the November 5 release, which arrives before the opening bell.

Analysts expect earnings of $0.09 a share on revenue of about $221.8 million. Last quarter Trulieve posted $271.0 million in revenue and $0.11 a share. Taken at face value, the Street is bracing for a sequential revenue decline of roughly 18%. That is a large step down for a vertically integrated operator whose medical footprint in Florida, Georgia, Pennsylvania and West Virginia has typically provided a steadier base than recreational-only markets. The earnings estimate falls by almost exactly the same proportion as revenue. In other words, analysts are not modeling a margin collapse. They are modeling a smaller business that earns roughly the same amount on each dollar of sales. That distinction matters. If revenue lands closer to the prior quarter's run rate, the earnings estimate could prove too low simply because the cost base would be spread over more sales.

There is no fresh company guidance to anchor the comparison, so the report itself will have to settle which picture is right. The first test is the top line. A result that tracks closer to $271 million than to $222 million would suggest the consensus was overly cautious, or built on stale assumptions. A figure near or below the estimate would confirm that something meaningful softened during the quarter, whether in volume, pricing or mix. In that case the explanation will matter as much as the number. A temporary dip is easier to forgive than evidence of structural price compression in core medical markets.

The second test is profitability. Vertically integrated cannabis companies live and die by gross margin, because they bear the cost of cultivation, processing and retail. If sales do fall sharply, holding margins steady would show real cost discipline. Slippage would raise the question of whether fixed cultivation and store costs are starting to bite. Cash generation and inventory levels deserve attention for the same reason. Rising inventory alongside falling sales would hint at a supply overhang. Lean inventory would suggest the company is matching production to demand.

Sentiment has swung decisively. Heading into the prior report, the mood was essentially neutral, tilting slightly bearish. It now reads firmly bullish. Paired with the stock's outperformance, that shift tells you expectations among investors appear meaningfully higher than the published estimates imply. At $10.67, the stock sits above its 200-day moving average of $10.16 and in the upper half of its post-earnings range of $8.51 to $12.93. Still, it is well short of that high, so this is not a stock pressing against a breakout level. That leaves room in both directions. A clean beat could renew the run toward the top of the range. A miss would hand back some of a rally that has already priced in improvement.

Ultimately, this report comes down to whether last quarter's $271 million was a durable base or a high-water mark. If Trulieve shows that revenue held up better than the Street feared while margins stayed intact, the market's optimism will look justified. If the sequential decline materializes and comes with margin pressure, the rally will have gotten ahead of the fundamentals.